RPE-Directed Gene Therapy Improves Mitochondrial Function in Murine Dry AMD Models.

Area of Science:

• Ophthalmology
• Genetics
• Mitochondrial Biology

Background:

• Age-related macular degeneration (AMD) is a leading cause of vision loss in older adults, with no effective treatments for the dry form.
• Dry AMD involves complex cellular degeneration, particularly in retinal pigment epithelium (RPE) and photoreceptor cells.
• Mitochondrial dysfunction is increasingly recognized as a critical factor in AMD pathogenesis.

Purpose of the Study:

• To evaluate the efficacy of RPE-specific gene therapy for dry AMD.
• To determine if targeting mitochondrial function in RPE cells can rescue AMD phenotypes.
• To assess the potential of using the VMD2 promoter for targeted gene delivery in dry AMD.

Main Methods:

• Adeno-associated virus (AAV) mediated gene delivery of the NADH-ubiquinone oxidoreductase (NDI1) gene.
• Expression of NDI1 driven by the RPE-specific Vitelliform macular dystrophy 2 (VMD2) promoter.
• Assessment of therapeutic benefit in established cellular and murine models of dry AMD.

Main Results:

• NDI1 gene therapy delivered via AAV demonstrated significant functional benefits in dry AMD models.
• Targeting NDI1 expression specifically to RPE cells using the VMD2 promoter showed therapeutic potential.
• RPE-specific delivery may offer improved safety by reducing off-target effects.

Conclusions:

• RPE-specific NDI1 gene therapy is a viable strategy for treating dry AMD.
• Targeting mitochondrial complex I function in RPE cells can ameliorate AMD pathology.
• This approach holds promise for developing safer and more effective dry AMD therapies.